NCT04354402View on ClinicalTrials.gov

Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL

CompletedOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

March 26, 2020

Primary Completion Date

November 11, 2020

Study Completion Date

November 11, 2020

Conditions
Diffuse Large B Cell Lymphoma
Interventions
OTHER

No intervention

No intervention

Trial Locations (17)

Unknown

Research Site, Nagoya

Research Site, Matsuyama

Research Site, Ōta

Research Site, Fukuyama

Research Site, Sapporo

Research Site, Sayama

Research Site, Izumo

Research Site, Chuo-ku

Research Site, Koto

Research Site, Shinagawa-ku

Research Site, Akita

Research Site, Fukuoka

Research Site, Ibaraki

Research Site, Kyoto

Research Site, Nagasaki

Research Site, Osaka

Research Site, Yamagata

Sponsors
All Listed Sponsors
lead

SymBio Pharmaceuticals

INDUSTRY

NCT04354402 - Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL | Biotech Hunter | Biotech Hunter